Stock theses tested in real time.
Yet Another Value Podcast treats public companies as live case studies, not headline fodder. Andrew Walker frames each episode around a stock, guest thesis, or market problem, then pushes into the mechanics that make the idea work or break.
PRESS PLAY
Yet Another Value Podcast is a brisk investing show centered on live public-market ideas. It is built for the moment after a ticker gets interesting and before the answer feels settled. Andrew Walker frames episodes around a company, a catalyst, or a market puzzle, then brings in guests who can argue through the details. The show has a clear value-investing core, but it often wanders into event-driven setups, biotech risk, media assets, software drawdowns, and odd situations where structure matters as much as valuation. One episode follows Fiserv through Clover customer checks and questions about what merchants actually like or dislike. Another turns Clear Security into a study of paid convenience, free alternatives, TSA line pain, subscription stickiness, and moat risk. Theravance becomes a risk-reward conversation around a strategic review. Marex gets compared against businesses such as Stonex and Interactive Brokers, with the focus on why a company can look obvious in hindsight and still feel difficult in the moment. The show is strongest when a guest brings primary work. It values the investor who called customers, read the filings, spoke with industry people, or lived close enough to the sector to know where the market may be lazy. The tone is plain and conversational. The substance can get technical quickly. Episodes may touch capital structures, pink-sheet liquidity, exchange relisting, dividend paths, clinical response rates, media assets, EBITDA declines, and sum-of-the-parts thinking. Walker also uses solo rambling episodes to stress-test his own frameworks, including sizing after sharp earnings moves and the rule of reassessing a stock that has gone nowhere for three years. It is opinionated without pretending to be final. The appeal is the process: a thesis gets opened, challenged, compared, qualified, and sometimes left unresolved. Listeners looking for polished market news may find it too granular. Investors who enjoy the mechanics of why a cheap stock might stay cheap, re-rate, or blow up will feel at home.
Made for: For investors and market obsessives who enjoy deep company-specific work. It suits listeners comfortable with valuation, catalysts, risk, and sector detail.
What sets it apart: The show’s edge is its willingness to stay inside the actual mechanics of an idea: customer checks, capital structure, liquidity, clinical data, relisting paths, and asset-level valuation. It feels closer to overhearing investors compare notes than consuming finished market commentary.
Yet Another Value Podcast is a new podcast from Andrew Walker, the founder of yetanothervalueblog.com/. We interview top investors and dive deep into stocks and companies they are currently working on and investing in. While nothing on this channel is investing advice and everyone should do their own diligence, our goal is to frequently feature edgy and actionable value and/or event driven ideas.Please see our legal and disclaimer at: https://yetanothervalueblog.substack.com/p/legal-and-disclaimer
Based on 5 episodes we listened to · September 2026
Andrew Walker pressure-tests stock theses by connecting company details, market structure and the assumptions investors can too easily leave unquestioned.
Yet Another Value Podcast treats an investment thesis as something to interrogate, with Andrew Walker pressing guests on valuation, catalysts and the assumptions holding a stock story together.
Andrew Walker asks the biotech question you were afraid to ask, then stays for the answer.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A sharp biotech discussion on response rates, hidden disease pathways, and unmet need as the start of an investment thesis.
Biotech investing becomes more tangible when the discussion moves from broad promise to the harder question of why an effective drug can still miss many patients.
A debt-heavy post-bankruptcy conversion frames a clear case study in liquidity, relisting, ownership, and dividend expectations.
FGPR's post-bankruptcy setup gives this episode a focused special-situations angle: a heavy debt load, a major conversion, and the possibility of better stock liquidity if a relisting comes through.
A skeptical, useful Versant breakup discussion that puts the golf assets at the center of the valuation case.
Versant comes through as a messy but interesting media breakup story, with the episode moving from golf-linked assets to studio logistics and then to the harder question of what the separated company might actually be worth.
A balance-sheet reset changes what a market sell-off can actually mean.
An investing discussion reframes a market sell-off as a test of balance-sheet durability. The host argues that many companies used the post-COVID cash-flow surge to repair their finances, then turns to U.S.
A coupon loophole and blocked mergers test how hands-on research can reshape an investor's view.
This episode turns a coupon loophole into a neat study of how business mechanics can slow down an otherwise decent product. The expert call lands on a wonderfully odd detail: stacking the company's coupon with several others could make products roughly 99% cheaper, yet the…
Demetri Kofinas interviews specialists on geopolitics, energy markets, AI, and finance at length.
BBC's daily business show, from toy-industry founders to Anthropic's Pentagon standoff.
Andrew Walker hosts a monthly 'Random Ramblings' episode covering four topics.
Andrew Walker hosts a solo rambling episode on March 15, 2025, discussing four main topics.
Andrew Walker interviews Shu from Guinea Value about his deep-dive research on Fiserv, including interviews with over 100 Clover customers.
Andrew Walker interviews Sean Emory about Clear Security, analyzing its unique business model and potential as an investment.
Andrew Walker and Andy Summers examine Theravance's strategic review after its Phase 3 drug failed and the stock fell roughly 30% to 35% to about $13.25.
Andrew Walker interviews Roderick from Nightwatch about Marex, ticker MRX, a futures commission merchant serving airlines, hedge funds, and other derivatives traders.
Andrew Walker's March 2026 random ramblings open with markets he calls "strange": on March 20 the S&P 500 is down 5% over the month and the VIX is near 26, yet the index is only down 4% for the year.
Biotech is risky.
The company is a messy special situation.
Andrew Walker frames Versant as Comcast’s cable spinoff, and Simeon McMillan says the 2028 ad-sales separation changes the stock’s economics.
Andrew Walker and Alex Morris of The Science of Hitting recorded this on March 6 as prep for Walker's March 10 AlphaSense webinar on Paramount's winning bid for Warner Bros.
Andrew Walker and Jeremy Raper discuss the post-mortem of an aviation leasing investment (AVAP), sharing lessons learned.
Andrew Walker interviews Evan Skorpen of Lead Edge Capital about growth tech investing, concentrated portfolios, and the impact of AI on software, with insights from Evan's experience on public company boards and private investments.
Andrew Walker interviews David Thomas, author of 'The Fairfax Way,' discussing Fairfax's history, investing strategy, and future prospects.
Andrew Walker interviews Doug O'Laughlin about AI, semiconductors, power, and corporate governance signals for investors.
Zack Buckley discusses the investment case for Basic Fit, a European fitness chain, and why the stock has underperformed despite bullish expectations.